(Q54449440)

English

CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).

scientific article published on 13 February 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23414588

CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23414588

0 references

1 reference

based on heuristic

inferred from title

Evandro de Azambuja

3

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23414588

Andrew M. Wardley

8

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23414588

author name string

Bernhard C Pestalozzi

1

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23414588

Eileen Holmes

2

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23414588

Otto Metzger-Filho

4

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23414588

Laurence Hogge

5

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23414588

Matt Scullion

6

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23414588

István Láng

7

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23414588

Mikhail Lichinitser

9

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23414588

Roberto I Lopez Sanchez

10

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23414588

Volkmar Müller

11

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23414588

David Dodwell

12

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23414588

Richard D Gelber

13

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23414588

Martine J Piccart-Gebhart

14

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23414588

David Cameron

15

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23414588

publication date

13 February 2013

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23414588

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23414588

14

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23414588

3

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23414588

244-248

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23414588

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970017-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970017-2

7 January 2021

based on heuristic

inferred from DOI database lookup

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970017-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970017-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970017-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant trastuzumab in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970017-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970017-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970017-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970017-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Central nervous system metastasis from breast carcinoma. Autopsy study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970017-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970017-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970017-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970017-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970017-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970017-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970017-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970017-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970017-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970017-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(13)70017-2

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23414588

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23414588

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54449440&oldid=1561175467"